Skip to main content

Table 3 Dosimetric results

From: Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments

  Parameter All Left breast Right breast
PTVWB Volume [cm3] 605.6 ± 313.9 702.5 ± 291.7 505.1 ± 309.5
  Mean [Gy] 41.5 ± 1.3 41.5 ± 1.3 41.5 ± 1.4
  D2% [Gy] 45.0 ± 1.3 44.8 ± 1.1 45.1 ± 1.5
  D98% [Gy] 37.2 ± 2.9 37.2 ± 3.1 37.3 ± 2.8
  V95% [%] 92.9 ± 12.8 93.0 ± 13.3 92.8 ± 12.6
  V105% [%] 30.8 ± 16.8 30.9 ± 16.0 30.7 ± 18.0
PTVboost Volume [cm3] 51.5 ± 45.9 54.11 ± 50.3 48.8 ± 41.7
  Mean [Gy] 47.8 ± 1.0 47.7 ± 1.1 48.0 ± 0.9
  D2% [Gy] 49.3 ± 0.9 49.1 ± 0.9 49.5 ± 0.9
  D98% [Gy] 45.8 ± 1.4 45.7 ± 1.6 45.8 ± 1.3
  V95% [%] 93.5 ± 19.9 92.5 ± 23.7 94.6 ± 15.4
  V105% [%] 0.7 ± 2.1 0.2 ± 0.7 1.2 ± 2.9
Ipsilateral Lung Mean [Gy] 8.7 ± 1.7 8.5 ± 1.7 8.9 ± 1.8
  V5Gy [%] 61.9 ± 15.9 60.0 ± 16.1 63.9 ± 15.9
  V20Gy [%] 8.6 ± 2.9 8.4 ± 2.8 8.8 ± 3.0
  V25Gy [%] 4.1 ± 1.9 4.2 ± 1.9 3.9 ± 1.9
Contralateral Lung Mean [Gy] 2.5 ± 0.9 2.6 ± 0.9 2.5 ± 1.0
  V5Gy [%] 8.9 ± 9.9 8.8 ± 9.7 9.1 ± 10.4
Heart Mean [Gy] 5.4 ± 2.0 6.5 ± 1.7 4.3 ± 1.8
  D1cm3 [Gy] 20.4 ± 8.9 27.0 ± 4.4 13.1 ± 6.4
  V18Gy [%] 2.0 ± 2.2 3.1 ± 3.3 0.5 ± 1.2
Skin 3 mm Mean [Gy] 21.0 ± 1.6 21.4 ± 1.8 20.7 ± 1.4
  V30Gy [cm3] 27.0 ± 12.5 29.6 ± 14.2 24.2 ± 9.9
  V40Gy [cm3] 0.5 ± 0.9 0.6 ± 1.1 0.5 ± 0.7
Skin 5 mm Mean [Gy] 23.3 ± 1.7 23.6 ± 1.8 22.9 ± 1.4
  V30Gy [cm3] 88.3 ± 26.7 96.0 ± 28.5 80.3 ± 22.6
  V40Gy [cm3] 5.9 ± 5.6 6.1 ± 6.5 5.6 ± 4.6
Ribs D1cm3 [Gy] 37.4 ± 2.6 37.4 ± 2.7 37.5 ± 2.5
  V40Gy [cm3] 3.2 ± 3.6 3.2 ± 3.9 3.2 ± 3.4
Contralateral Breast Mean [Gy] 3.3 ± 5.8 4.1 ± 8.2 2.5 ± 0.6
  V5Gy [%] 7.6 ± 15.0 10.0 ± 20.3 5.1 ± 4.8
Healthy Tissue Mean [Gy] 3.4 ± 0.7 3.3 ± 0.6 3.5 ± 0.7
  V10Gy [%] 9.2 ± 2.2 8.8 ± 1.9 9.6 ± 2.3
  DoseInt [Gy*cm3*104]* 7.2 ± 2.0 7.6 ± 1.9 6.8 ± 2.0
  1. * DoseInt = integral dose.